English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Nowadays, treatment of food allergy only considered the avoidance of the specific food. However, the possibility of cross-reactivity makes this practice not very effective. Immunotherapy may exhibit as a good alternative to food allergy treatment. The use of hypoallergenic molecules with reduced IgE binding capacity but with ability to stimulate the immune system is a promising tool which could be developed for immunotherapy. In this study, three mutants of Pru p 3, the principal allergen of peach, were produced based on the described mimotope and T cell epitopes, by changing the specific residues to alanine, named as  Pru p 3.01, Pru p 3.02 , and  Pru p 3.03 .  Pru p 3.01  showed very similar allergenic activity as the wild type by  in vitro  assays. However,  Pru p 3.02  and  Pru p 3.03  presented reduced IgE binding with respect to the native form, by  in vitro ,  ex vivo,  and in vivo assays. In addition,  Pru p 3.03  had affected the IgG4 binding capacity and presented a random circular dichroism, which was reflected in the nonrecognition by specific antibodies anti-Pru p 3. Nevertheless, both  Pru p 3.02  and  Pru p 3.03  maintained the binding to IgG1 and their ability to activate T lymphocytes. Thus,  Pru p 3.02  and  Pru p 3.03  could be good candidates for potential immunotherapy in peach-allergic patients.

Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines